MarketPulse

certepetide

2 articles
BenzingaBenzinga··Globe Newswire

Lisata Therapeutics to Be Acquired by Kuva Labs for $5 Per Share Plus Contingent Payments

Lisata Therapeutics agreed to be acquired by Kuva Labs for $5.00 per share plus up to $1.00 contingent payment, closing expected in Q2 2026.
LSTAacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lisata Therapeutics to Be Acquired by Kuva Labs for $5 Per Share Plus Milestone Payment

Lisata Therapeutics agrees to be acquired by Kuva Labs for $5 per share plus up to $1 contingent payment tied to FDA approval, with close expected in Q2 2026.
LSTAacquisitionFDA approval